Amendments To The Claims

1-20. (Canceled)

21. (Currently amended) A method of treating B cell lymphoma in a human subject comprising administering a chimeric anti-CD20 antibody having a variable light chain comprising the amino acid sequence encoded by the nucleic acid ~~of SEQ ID NO:5~~ of SEQ ID NO:3 and a variable heavy chain encoded by the nucleic acid ~~of SEQ ID NO:10~~ of SEQ ID NO:5.

22. (Previously presented) The method of Claim 21 wherein said B cell lymphoma is relapsed B cell lymphoma.

23. (Previously presented) The method of Claim 21 wherein said chimeric anti-CD20 antibody is administered parenterally.

24. (Previously presented) The method of Claim 23 wherein parenteral administration is selected from the group consisting of intravenous, intramuscular, rectal, vaginal, subcutaneous and intraperitoneal.

25. (Previously presented) The method of Claim 23 wherein administration is by intravenous administration.

26. (Previously presented) The method of Claim 21 wherein said chimeric anti-CD20 antibody is administered in a single dosage.

27. (Previously presented) The method of Claim 26 wherein said dose ranges from about 0.001 to 30 mg/kg body weight.

28. (Previously presented) The method of Claim 26 wherein said dosage ranges from about 0.01 to about 25 mg/kg body weight.

29. (Previously presented) The method of Claim 26 wherein said dosage ranges from about 0.4 to about 20.0 mg/kg body weight.

30. (Currently amended) A method for treating a peripheral blood B cell disorder comprising administering a chimeric anti-CD20 antibody having a variable light chain comprising the amino acid sequence encoded by the nucleic acid ~~of SEQ ID NO:5~~ of SEQ ID NO:3 and a variable heavy chain encoded by the nucleic acid ~~of SEQ ID NO:10~~ of SEQ ID NO:5.

31. (Previously presented) The method of Claim 30 wherein said chimeric antibody is administered together with chemotherapy or radiotherapy.

32. (Previously presented) The method of Claim 30 wherein said chimeric anti-CD20 antibody is administered parenterally.

33. (Previously presented) The method of Claim 32 wherein parenteral administration is selected from the group consisting of intravenous, intramuscular, rectal, vaginal, subcutaneous and intraperitoneal.

34. (Previously presented) The method of Claim 32 wherein administration is by intravenous administration.

35. (Previously presented) The method of Claim 30 wherein said chimeric anti-CD20 antibody is administered in a single dosage.

36. (Previously presented) The method of Claim 35 wherein said dose ranges from about 0.001 to 30 mg/kg body weight.

37. (Previously presented) The method of Claim 35 wherein said dosage ranges from about 0.01 to about 25 mg/kg body weight.

38. (Previously presented) The method of Claim 35 wherein said dosage ranges from about 0.4 to about 20.0 mg/kg body weight.

39. (Previously presented) The method of Claim 21 which additionally comprises radiotherapy.

40. (Previously presented) The method of Claim 21 which additionally comprises chemotherapy.

41. (Previously presented) The method of Claim 30 which additionally includes radiotherapy.

42. (Previously presented) The method of Claim 30 which additionally includes chemotherapy.

43. (Previously presented) The method of Claim 21 wherein said chimeric anti-CD20 antibody is administered in several dosages.

44. (Previously presented) The method of Claim 43 wherein said doses are administered over a time period of about one to four weeks.

45. (Previously presented) The method of Claim 20 wherein the chimeric anti-CD20 antibody is an IgG1.

46. (Previously presented) The method of Claim 30 wherein the chimeric anti-CD20 antibody is an IgG1.

47. (Previously presented) The method of Claim 21 which comprises the administration of a radiolabel.

48. (Previously presented) The method of Claim 47 wherein said radiolabel is attached to said chimeric anti-CD20 antibody.

49. (Previously presented) The method of Claim 47 wherein said radiolabel is attached to a different anti-CD20 antibody.

50. (Previously presented) The method of Claim 49 wherein said different anti-CD20 antibody is murine.

51. (Previously presented) The method of Claim 50 wherein said murine anti-CD20 antibody comprises the same variable region as said chimeric anti-CD20 antibody.

52. (Previously presented) The method of Claim 47 wherein said radiolabel is selected from the group consisting of yttrium (90), iodine (131) and indium (111).

53. (Previously presented) The method of Claim 52 wherein the radiolabel is yttrium (90).

54. (Previously presented) The method of Claim 41 wherein said radiolabel is selected from the group consisting of yttrium (90), iodine (131) and indium (111).

55. (Previously presented) The method of Claim 54 wherein the radiolabel is yttrium (90).

56. (Previously presented) The method of Claim 55 wherein the different anti-CD20 antibody is a murine anti-CD20 antibody.

57. (Previously presented) The method of Claim 56 wherein the radiolabel is yttrium (90).

58. (Previously presented) The method of Claim 56 wherein the murine anti-CD20 antibody comprises the same variable region as the chimeric anti-CD20 antibody.

59. (Previously presented) The method of Claim 57 which further comprises chemotherapy.

60. (Currently amended) A method of treating B cell lymphoma comprising administering a therapeutically effective amount of an anti-CD20 antibody comprising a variable light chain encoded by the nucleic acid ~~of SEQ ID NO:5~~ of SEQ ID NO:3.

61. (Currently amended) A method of treating B cell lymphoma comprising administering a therapeutically effective amount of an anti-CD20 antibody comprising a variable heavy chain encoded by the nucleic acid ~~of SEQ ID NO:10~~ of SEQ ID NO:5.

62. (Previously presented) The method of Claim 60 wherein the antibody is radiolabeled.

63. (Previously presented) The method of Claim 61 wherein the antibody is radiolabeled.

64. (Previously presented) The method of Claim 60 which additionally includes chemotherapy.

65. (Previously presented) The method of Claim 61 which additionally includes chemotherapy.

66. (Previously presented) The method of Claim 64 wherein the chemotherapy is selected from the group consisting of doxorubicin, vincristine, cyclophosphamide and prednisone.

67. (Previously presented) The method of Claim 65 where the chemotherapy is selected from the group consisting of doxorubicin, vincristine, cyclophosphamide and prednisone.

68. (Previously presented) The method of Claim 62 wherein the radiolabel is yttrium (90) or iodine (131).

69. (Previously presented) The method of Claim 62 wherein the radiolabel is iodine (131) or yttrium (90).